[
  {
    "ts": "2026-01-13T02:06:44+00:00",
    "headline": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
    "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
    "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
      "content": {
        "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
        "contentType": "STORY",
        "title": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
        "description": "",
        "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
        "pubDate": "2026-01-13T02:06:44Z",
        "displayTime": "2026-01-13T02:06:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Adaptive Biotechnologies logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vl3KxAbO6Qy1kY4gwcWiQw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k0aX39WhsUnMUyzB.8sxJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adaptive-biotechnologies-touts-clonoseq-mrd-020644870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADPT"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T11:00:20+00:00",
    "headline": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
    "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
    "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "64d9b4ee-82fe-36a2-9d94-b93d5871bdb7",
      "content": {
        "id": "64d9b4ee-82fe-36a2-9d94-b93d5871bdb7",
        "contentType": "STORY",
        "title": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
        "description": "",
        "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
        "pubDate": "2026-01-13T11:00:20Z",
        "displayTime": "2026-01-13T11:00:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T10:24:00+00:00",
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
      "content": {
        "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
        "contentType": "STORY",
        "title": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
        "description": "",
        "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
        "pubDate": "2026-01-13T10:24:00Z",
        "displayTime": "2026-01-13T10:24:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f/abbvie-strikes-a-100-billion.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uprYtz96.huIUAIJcxlT7w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LhuGYFvbZhLBqQD88UWabQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]